Soundwatch Capital LLC Acquires New Position in Teva Pharmaceutical Industries Ltd. $TEVA

Soundwatch Capital LLC bought a new position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the second quarter, Holdings Channel.com reports. The institutional investor bought 8,564,012 shares of the company’s stock, valued at approximately $143,533,000. Teva Pharmaceutical Industries accounts for approximately 0.7% of Soundwatch Capital LLC’s portfolio, making the stock its 13th largest holding.

Several other institutional investors and hedge funds have also made changes to their positions in TEVA. US Bancorp DE grew its position in shares of Teva Pharmaceutical Industries by 6.5% in the first quarter. US Bancorp DE now owns 10,812 shares of the company’s stock valued at $166,000 after purchasing an additional 656 shares in the last quarter. MAI Capital Management boosted its stake in Teva Pharmaceutical Industries by 26.8% during the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock worth $55,000 after buying an additional 697 shares during the last quarter. Wedbush Securities Inc. boosted its stake in Teva Pharmaceutical Industries by 3.3% during the second quarter. Wedbush Securities Inc. now owns 21,995 shares of the company’s stock worth $369,000 after buying an additional 700 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Teva Pharmaceutical Industries by 15.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,474 shares of the company’s stock valued at $92,000 after buying an additional 715 shares in the last quarter. Finally, CWM LLC increased its stake in shares of Teva Pharmaceutical Industries by 18.1% in the 2nd quarter. CWM LLC now owns 4,995 shares of the company’s stock worth $84,000 after acquiring an additional 767 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 200,000 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total value of $4,822,000.00. Following the sale, the director owned 495,000 shares of the company’s stock, valued at $11,934,450. The trade was a 28.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.49% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on TEVA shares. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 11th. JPMorgan Chase & Co. raised their price objective on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. Finally, UBS Group increased their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $25.86.

Teva Pharmaceutical Industries Stock Down 0.5%

Shares of NYSE:TEVA opened at $24.16 on Friday. The company has a market capitalization of $27.71 billion, a price-to-earnings ratio of -151.00, a PEG ratio of 1.11 and a beta of 0.70. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $26.38. The business has a 50-day moving average price of $20.87 and a 200 day moving average price of $18.52. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, November 5th. The company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.10. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The company had revenue of $4.48 billion during the quarter, compared to analyst estimates of $4.36 billion. During the same quarter last year, the firm posted $0.69 earnings per share. Teva Pharmaceutical Industries’s revenue was up 3.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. Sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.